Company history

The company was founded out of the University of Twente and has an R&D facility within the TechMed Centre in Enschede and offices at the Bio Science Park Leiden.

In 2018, 20Med closed a financing round of €3.3 Million for the development of RNA based therapeutics and vaccines. In addition to being the backbone of the in-house development programs, 20Med’s propriety delivery technology is currently being utilized in a number of collaborations with leading biotech and pharma companies as well as in several European projects with applications in intra-tumoral, intra-articular and brain delivery.